Treatment options for carcinoma in situ testis

International Journal of Andrology

Volumn 34, Issue 4 PART 2, 2011, Pages

  Mortensen, M S ^a   Gundgaard, M G ^a   Daugaard, G ^a  

^a Rigshospitalet   (Denmark)

Author keywords

Cancer; Carcinoma in situ testis; Hormone treatment; Testicular biopsy; Testicular neoplasms; Treatment

Indexed keywords

ANDROGEN; BLEOMYCIN; CISPLATIN; ETOPOSIDE;

ANDROGEN DEFICIENCY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CARCINOMA IN SITU; CRYOPRESERVATION; EXTRAGONADAL GERM CELL CANCER; GERM CELL TUMOR; HIGH RISK PATIENT; HORMONE SUBSTITUTION; HUMAN; MULTIMODALITY CANCER THERAPY; ORCHIECTOMY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TESTICULAR CARCINOMA IN SITU; TESTIS CARCINOMA; TESTIS CARCINOMA IN SITU; TREATMENT OUTCOME; TUMOR BIOPSY;

CARCINOMA IN SITU; COMBINED MODALITY THERAPY; CRYOPRESERVATION; HUMANS; MALE; NEOPLASMS, GERM CELL AND EMBRYONAL; ORCHIECTOMY; TESTICULAR NEOPLASMS;

EID: 79960890720     PISSN: 01056263     EISSN: 13652605     Source Type: Journal    
DOI: 10.1111/j.1365-2605.2011.01178.x     Document Type: Review

References (36)

1. Albers P, Albrecht W, Algaba F, Bokemeyer C, Cohn-Cedermark G, Fizazi K, Horwich A & Laguna MP. (2010) Guidelines on Testicular Cancer. European Association of Urology, Available at.
2. Bang AK, Petersen JH, Petersen PM, Andersson AM, Daugaard G & Jorgensen N. (2009) Testosterone production is better preserved after 16 than 20 Gray irradiation treatment against testicular carcinoma in situ cells. Int J Radiat Oncol Biol Phys 75, 672-676.
3. Bohle A, Studer UE, Sonntag RW & Scheidegger JR. (1986) Primary or secondary extragonadal germ cell tumors? J Urol 135, 939-943.
4. Bottomley D, Fisher C, Hendry WF & Horwich A. (1990) Persistent carcinoma in situ of the testis after chemotherapy for advanced testicular germ cell tumours. Br J Urol 66, 420-424.
5. Chong C, Logothetis CJ, von Eschenbach A, Ayala A & Samuels M. (1986) Orchiectomy in advanced germ cell cancer following intensive chemotherapy: a comparison of systemic to testicular response. J Urol 136, 1221-1223.
6. Christensen TB, Daugaard G, Geertsen PF & von der Maase H (1998) Effect of chemotherapy on carcinoma in situ of the testis. Ann Oncol 9, 657-660.
7. Classen J, Dieckmann K, Bamberg M, Souchon R, Kliesch S, Kuehn M & Loy V. (2003) Radiotherapy with 16Gy may fail to eradicate testicular intraepithelial neoplasia: preliminary communication of a dose-reduction trial of the German Testicular Cancer Study Group. Br J Cancer 88, 828-831.
8. Daugaard G, von der Maase H, Olsen J, Rorth M & Skakkebaek NE. (1987) Carcinoma-in-situ testis in patients with assumed extragonadal germ-cell tumours. Lancet 2, 528-530.
9. Dieckmann KP (1988) Residual carcinoma-in-situ of contralateral testis after chemotherapy. Lancet 1, 765.
10. Dieckmann KP & Loy V. (1995) Intratesticular effects of cisplatin-based chemotherapy. Eur Urol 28, 25-30.
11. Dieckmann KP & Skakkebaek NE. (1999) Carcinoma in situ of the testis: review of biological and clinical features. Int J Cancer 83, 815-822.
12. Dieckmann KP, Lauke H, Michl U, Winter E & Loy V. (2002) Testicular germ cell cancer despite previous local radiotherapy to the testis. Eur Urol 41, 643-649 discussion 649-650.
13. Dieckmann KP, Kulejewski M, Pichlmeier U & Loy V. (2007) Diagnosis of contralateral testicular intraepithelial neoplasia (TIN) in patients with testicular germ cell cancer: systematic two-site biopsies are more sensitive than a single random biopsy. Eur Urol 51, 175-183 discussion 183-175.
14. Dotsch M, Brauers A, Buttner R, Nolte-Ernsting C, Eble MJ & Jakse G. (2000) Malignant germ cell tumor of the contralateral testis after radiotherapy for testicular intraepithelial neoplasia. J Urol 164, 452-453.
15. Fossa SD, Aass N, Heilo A, Daugaard G, Skakkebaek NE, Stenwig AE, Nesland JM, Looijenga LH & Oosterhuis JW. (2003) Testicular carcinoma in situ in patients with extragonadal germ-cell tumours: the clinical role of pretreatment biopsy. Ann Oncol 14, 1412-1418.
16. Fossa SD, Chen J, Schonfeld SJ, McGlynn KA, McMaster ML, Gail MH & Travis LB. (2005) Risk of contralateral testicular cancer: a population-based study of 29, 515 U.S. men. J Natl Cancer Inst 97, 1056-1066.
17. Giwercman A, von der Maase H, Berthelsen JG, Rorth M, Bertelsen A & Skakkebaek NE. (1991) Localized irradiation of testes with carcinoma in situ: effects on Leydig cell function and eradication of malignant germ cells in 20 patients. J Clin Endocrinol Metab 73, 596-603.
18. Giwercman A, von der Maase H & Skakkebaek NE. (1993) Epidemiological and clinical aspects of carcinoma in situ of the testis. Eur Urol 23, 104-110 discussion 111-104.
19. Greist A, Einhorn LH, Williams SD, Donohue JP & Rowland RG. (1984) Pathologic findings at orchiectomy following chemotherapy for disseminated testicular cancer. J Clin Oncol 2, 1025-1027.
20. Hartmann JT, Fossa SD, Nichols CR, Droz JP, Horwich A, Gerl A et al. (2001) Incidence of metachronous testicular cancer in patients with extragonadal germ cell tumors. J Natl Cancer Inst 93, 1733-1738.
21. Kleinschmidt K, Dieckmann KP, Georgiew A, Loy V & Weissbach L. (2009) Chemotherapy is of limited efficacy in the control of contralateral testicular intraepithelial neoplasia in patients with testicular germ cell cancer. Oncology 77, 33-39.
22. Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F et al. (2008) European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol 53, 478-496.
23. von der Maase H, Rorth M, Walbom-Jorgensen S, Sorensen BL, Christophersen IS, Hald T, Jacobsen GK, Berthelsen JG & Skakkebaek NE. (1986) Carcinoma in situ of contralateral testis in patients with testicular germ cell cancer: study of 27 cases in 500 patients. Br Med J (Clin Res Ed) 293, 1398-1401.
24. von der Maase H, Meinecke B & Skakkebaek NE. (1988) Residual carcinoma-in-situ of contralateral testis after chemotherapy. Lancet 1, 477-478.
25. Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA et al. (2009) NCCN clinical practice guidelines in oncology: testicular cancer. J Natl Compr Canc Netw 7, 672-693.
26. Olesen IA, Hoei-Hansen CE, Skakkebaek NE, Petersen JH, Rajpert-De Meyts E & Jorgensen N. (2007) Testicular carcinoma in situ in subfertile Danish men. Int J Androl 30, 406-411 discussion 412.
27. Pamenter B, De Bono JS, Brown IL, Nandini M, Kaye SB, Russell JM, Yates AJ & Kirk D (2003) Bilateral testicular cancer: a preventable problem? Experience from a large cancer centre. BJU Int 92, 43-46.
28. Petersen PM, Giwercman A, Hansen SW, Berthelsen JG, Daugaard G, Rorth M & Skakkebaek NE. (1999) Impaired testicular function in patients with carcinoma-in-situ of the testis. J Clin Oncol 17, 173-179.
29. Petersen PM, Giwercman A, Daugaard G, Rorth M, Petersen JH, Skakkeaek NE, Hansen SW & von der Maase H. (2002) Effect of graded testicular doses of radiotherapy in patients treated for carcinoma-in-situ in the testis. J Clin Oncol 20, 1537-1543.
30. Rorth M, Rajpert-De Meyts E, Andersson L, Dieckmann KP, Fossa SD, Grigor KM et al. (2000) Carcinoma in situ in the testis. Scand J Urol Nephrol Suppl 205, 166-186.
31. Schmoll HJ, Jordan K, Huddart R, Pes MP, Horwich A, Fizazi K & Kataja V. (2010) Testicular seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl. 5), v140-v146.
32. Setchell BP. (1980) The functional significance of the blood-testis barrier. J Androl 1, 3-10.
33. Simmonds PD, Mead GM, Lee AH, Theaker JM, Dewbury K & Smart CJ. (1995) Orchiectomy after chemotherapy in patients with metastatic testicular cancer. Is it indicated? Cancer 75, 1018-1024.
34. Skakkebaek NE, Rajpert-De Meyts E & Main KM. (2001) Testicular dysgenesis syndrome: an increasingly common developmental disorder with environmental aspects. Hum Reprod 16, 972-978.
35. Theodore C, Terrier-Lacombe MJ, Laplanche A, Benoit G, Fizazi K, Stamerra O & Wibault P. (2004) Bilateral germ-cell tumours: 22-year experience at the Institut Gustave Roussy. Br J Cancer 90, 55-59.
36. Wood L, Kollmannsberger C, Jewett M, Chung P, Hotte S, O'Malley M et al. (2010) Canadian consensus guidelines for the management of testicular germ cell cancer. Can Urol Assoc J 4, e19-e38.